Press Releases Year All News20192018201720162015 Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights November 12, 2019 bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy November 12, 2019 Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual Meeting November 6, 2019 Forty Seven Inc. to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 November 5, 2019 Forty Seven Inc. to Present at 2019 Cantor Global Healthcare Conference September 27, 2019 Forty Seven Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference September 3, 2019 Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia September 3, 2019 Forty Seven Inc. Reports Second Quarter 2019 Financial Results and Recent Business Highlights August 13, 2019 Forty Seven Inc. to Report Second Quarter 2019 Financial Results on Tuesday, August 13, 2019 August 6, 2019 Forty Seven, Inc. Announces $6 Million in Funding from the Leukemia & Lymphoma Society TAP to Accelerate the Development of 5F9 in Myelodysplastic Syndrome August 6, 2019 Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 29
